Scaling manufacturing and commercialization for an autologous CAR-T therapy like Carvykti is too complex for a small biotech alone. Legend Biotech's partnership with J&J was critical, combining Legend's science with J&J's global manufacturing, clinical development, and commercial muscle.

After the Synthes merger slowed internal R&D, J&J revitalized its pipeline by building a 10-15 year external innovation strategy. This team, led by Nick Pachuda, focused on key areas like robotics and AI, then invested in and collaborated with dozens of early-stage companies to fill strategic gaps.

Johnson & Johnson's two recent platform deals for in vivo CAR-T technology (with SAIL Biomedicines and Colonia) strongly suggest it will not acquire its existing ex vivo CAR-T partner, Legend Biotech. By building its own next-generation capabilities, J&J has less strategic incentive to buy Legend.

In a highly technical field like radiopharmaceuticals, success requires combining distinct capabilities. Crown Bioscience's partnership with Medicine Discovery Catapult merges preclinical modeling expertise with radiolabeling know-how, creating a comprehensive service offering that would be difficult for one organization to build alone.

J&J overcame skepticism about Legend's impressive but China-based CAR-T data by conducting deep, on-the-ground due diligence. They reviewed patient records and documentation to confirm the data's integrity, which became the foundation for a highly successful global partnership.

For pre-revenue biotechs like Voyager, partnering provides non-dilutive capital. More importantly, it de-risks development by sharing costs and leveraging a larger company's resources and expertise. This can increase a drug's probability of success, a crucial factor when most programs fail.

To overcome production bottlenecks, Legend Biotech employs a diversified manufacturing strategy. They operate their own large facilities in the US and Belgium while also contracting with pharmaceutical giant Novartis to produce their CAR T therapy. This enables a rapid scale-up to a planned 10,000 annual doses.

Alan Bash describes Legend Biotech as a 'Goldilocks company.' It has an approved, blockbuster therapy, a strong balance sheet, and a pipeline, providing stability. Yet, it maintains a small, agile culture focused on fast decision-making, offering the best of both worlds.

The immense capital investment needed to build global manufacturing and commercial infrastructure makes it nearly impossible for most startup or mid-stage cell therapy companies to scale independently. According to Kite's Cindy Perettie, partnering with a large pharmaceutical company is a practical necessity for reaching global markets.